203 related articles for article (PubMed ID: 36762066)
1. Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR/Cas9-mediated gene-disruptions corroborate the
Vad-Nielsen J; Staunstrup NH; Kjeldsen ML; Dybdal N; Flandin G; De Stradis C; Daugaard TF; Vilsbøll-Larsen T; Maansson CT; Doktor TK; Sorensen BS; Nielsen AL
Transl Lung Cancer Res; 2023 Jan; 12(1):42-65. PubMed ID: 36762066
[TBL] [Abstract][Full Text] [Related]
2. Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells.
Vad-Nielsen J; Gammelgaard KR; Daugaard TF; Nielsen AL
Lung Cancer; 2019 Jun; 132():132-140. PubMed ID: 31097086
[TBL] [Abstract][Full Text] [Related]
3.
Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
[TBL] [Abstract][Full Text] [Related]
4. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Yoshida T; Song L; Bai Y; Kinose F; Li J; Ohaegbulam KC; Muñoz-Antonia T; Qu X; Eschrich S; Uramoto H; Tanaka F; Nasarre P; Gemmill RM; Roche J; Drabkin HA; Haura EB
PLoS One; 2016; 11(1):e0147344. PubMed ID: 26789630
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of
Clement MS; Gammelgaard KR; Nielsen AL; Sorensen BS
Transl Lung Cancer Res; 2020 Oct; 9(5):1904-1914. PubMed ID: 33209611
[TBL] [Abstract][Full Text] [Related]
6. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.
Ware KE; Hinz TK; Kleczko E; Singleton KR; Marek LA; Helfrich BA; Cummings CT; Graham DK; Astling D; Tan AC; Heasley LE
Oncogenesis; 2013 Mar; 2(3):e39. PubMed ID: 23552882
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway.
Lu Y; Liu Y; Oeck S; Zhang GJ; Schramm A; Glazer PM
Cancer Res; 2020 Nov; 80(21):4655-4667. PubMed ID: 32873635
[TBL] [Abstract][Full Text] [Related]
8. Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC.
Huang J; Lan X; Wang T; Lu H; Cao M; Yan S; Cui Y; Jia D; Cai L; Xing Y
Oncogene; 2020 Feb; 39(8):1739-1755. PubMed ID: 31740781
[TBL] [Abstract][Full Text] [Related]
9. The regulatory role of APE1 in epithelial-to-mesenchymal transition and in determining EGFR-TKI responsiveness in non-small-cell lung cancer.
Yang X; Peng Y; Jiang X; Lu X; Duan W; Zhang S; Dai N; Shan J; Feng Y; Li X; Cheng Y; Yang Y; Baugh L; Tell G; Wang D; Li M
Cancer Med; 2018 Sep; 7(9):4406-4419. PubMed ID: 30109782
[TBL] [Abstract][Full Text] [Related]
10. Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features.
Sato H; Shien K; Tomida S; Okayasu K; Suzawa K; Hashida S; Torigoe H; Watanabe M; Yamamoto H; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S
Sci Rep; 2017 Jan; 7():40847. PubMed ID: 28084458
[TBL] [Abstract][Full Text] [Related]
11. DCLK1 Drives EGFR-TKI-Acquired Resistance in Lung Adenocarcinoma by Remodeling the Epithelial-Mesenchymal Transition Status.
Yan R; Huang X; Liu H; Xiao Z; Liu J; An G; Ge Y
Biomedicines; 2023 May; 11(5):. PubMed ID: 37239162
[TBL] [Abstract][Full Text] [Related]
12. Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.
Iderzorig T; Kellen J; Osude C; Singh S; Woodman JA; Garcia C; Puri N
Biochem Biophys Res Commun; 2018 Feb; 496(2):770-777. PubMed ID: 29337056
[TBL] [Abstract][Full Text] [Related]
13. The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Jakobsen KR; Demuth C; Sorensen BS; Nielsen AL
Transl Lung Cancer Res; 2016 Apr; 5(2):172-82. PubMed ID: 27186512
[TBL] [Abstract][Full Text] [Related]
14. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Raoof S; Mulford IJ; Frisco-Cabanos H; Nangia V; Timonina D; Labrot E; Hafeez N; Bilton SJ; Drier Y; Ji F; Greenberg M; Williams A; Kattermann K; Damon L; Sovath S; Rakiec DP; Korn JM; Ruddy DA; Benes CH; Hammerman PS; Piotrowska Z; Sequist LV; Niederst MJ; Barretina J; Engelman JA; Hata AN
Oncogene; 2019 Sep; 38(37):6399-6413. PubMed ID: 31324888
[TBL] [Abstract][Full Text] [Related]
15. Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC.
Gammelgaard KR; Vad-Nielsen J; Clement MS; Weiss S; Daugaard TF; Dagnæs-Hansen F; Meldgaard P; Sorensen BS; Nielsen AL
Transl Oncol; 2019 Mar; 12(3):432-440. PubMed ID: 30562682
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylation, as opposed to promoter methylation, results in epigenetic
Zhao M; Zhang Y; Li J; Li X; Cheng N; Wang Q; Cai W; Zhao C; He Y; Chang J; Zhou C
Oncol Lett; 2018 Jan; 15(1):1089-1096. PubMed ID: 29399169
[TBL] [Abstract][Full Text] [Related]
17. Alisertib inhibits migration and invasion of EGFR-TKI resistant cells by partially reversing the epithelial-mesenchymal transition.
Wang CY; Lee MH; Kao YR; Hsiao SH; Hong SY; Wu CW
Biochim Biophys Acta Mol Cell Res; 2021 May; 1868(6):119016. PubMed ID: 33744274
[TBL] [Abstract][Full Text] [Related]
18. Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review.
Liu L; Wang C; Li S; Bai H; Wang J
Transl Lung Cancer Res; 2021 Sep; 10(9):3823-3839. PubMed ID: 34733631
[TBL] [Abstract][Full Text] [Related]
19.
He Z; Gong F; Liao J; Wang Q; Su Y; Chen C; Lin J; Lin RJ
Transl Cancer Res; 2020 Apr; 9(4):2542-2555. PubMed ID: 35117614
[TBL] [Abstract][Full Text] [Related]
20. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
Li XF; Shen WZ; Jin X; Ren P; Zhang J
Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
